Why Is Vaxcyte (PCVX) Stock Down -8.93% Today?
Key Takeaways
- Vaxcyte shares fell about 8.93% to roughly $67.23 intraday, retreating from Monday's closing price of $73.82.
- Primary catalyst: a $1 billion dual capital raise—$500 million in common stock and pre-funded warrants plus $500 million in convertible senior notes—announced after Monday's close, diluting existing shareholders.
- Secondary driver: profit-taking after the stock surged roughly 31% Monday on positive Phase 3 data for its VAX-31 pneumococcal vaccine.
- Broader context: the pullback is a financing-driven move rather than a reflection of deteriorating fundamentals, with shares still far above the $56.48 close before the data readout.
- What traders are watching next: final pricing of the offerings, plus Phase 3 OPUS-2 and OPUS-3 results expected in the first half of 2027.
Opening Summary
Shares of PCVX, the San Carlos, California-based clinical-stage vaccine developer Vaxcyte, Inc., fell 8.93% in Tuesday's session, trading near $67.23 versus a prior close of $73.82. The decline followed the company's announcement late Monday of a $1 billion dual public offering, a dilutive financing that outweighed the afterglow of a landmark clinical win the previous day. While the move marks a sharp reversal, it comes after one of the stock's strongest sessions on record, leaving shares substantially higher than their pre-announcement levels.
A $1 Billion Capital Raise Pressures the Share Price
The immediate catalyst for Tuesday's decline was Vaxcyte's decision to capitalize on its surging valuation. The company launched an underwritten offering of $500 million in common stock and pre-funded warrants alongside $500 million in convertible senior notes due October 15, 2032. Underwriters were granted a 30-day option to purchase up to an additional $75 million in each offering to cover over-allotments.
Equity and convertible offerings are typically dilutive to existing shareholders, and investors frequently sell shares when a company announces new issuance. By pairing common stock with a convertible note, Vaxcyte is raising substantial growth capital while creating the potential for further future dilution if the notes convert. The company said net proceeds would fund clinical development of its VAX-31 adult and pediatric programs, including ongoing Phase 3 trials, as well as manufacturing scale-up, commercial launch preparations, and early-stage pipeline research.
Profit-Taking After Monday's Clinical Breakthrough
The financing move also triggered natural profit-taking after an extraordinary rally. On Monday, Vaxcyte announced positive topline results from OPUS-1, its pivotal adult Phase 3 trial of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate. The vaccine met all prespecified co-primary immunogenicity endpoints in adults 50 and older, matching immune responses against PFE (Pfizer)'s Prevnar 20 on all 20 shared serotypes and against MRK (Merck)'s Capvaxive on 17 of 19 shared serotypes, while showing superiority on three strains unique to VAX-31.
That result sent shares up roughly 31% on Monday, closing at $73.82 after touching an intraday high of $90.75, and drew a wave of analyst price-target increases. The subsequent capital raise, announced within hours of the data readout, suggested management was moving quickly to fund the program at an opportune moment—an interpretation that prompted some investors to lock in gains rather than absorb dilution.
Market Context and Trading Activity
The move reflects company-specific financing dynamics rather than broad sector weakness. Monday's rally had lifted the broader vaccine group, with peers such as NVAX and MRNA also advancing on the readout and unrelated reports of a suspected plague outbreak in Russia. Tuesday's pullback in PCVX, by contrast, was concentrated in the stock itself as investors digested the size and structure of the new issuance. Even after the decline, the shares remain sharply elevated versus their $56.48 close before the data, underscoring that the financing decision—not the underlying science—is driving the immediate selling pressure.
What Comes Next for PCVX
The key near-term variable is the final pricing of the two offerings and whether underwriters exercise their over-allotment options, which will determine the full scope of dilution. Beyond financing, Vaxcyte expects to report results from two additional adult Phase 3 trials, OPUS-2 and OPUS-3, in the first half of 2027, with infant Phase 2 data also due by mid-2027. The company plans to submit a Biologics License Application to the U.S. Food and Drug Administration in the first half of 2028. Risks include the company's lack of any approved product, substantial ongoing cash burn, and the inherent uncertainty of remaining clinical readouts and regulatory review.
Trending AI Robots
For investors seeking a systematic approach to navigating volatile markets, Tickeron's Trending AI Robots page highlights the platform's top-performing automated trading strategies. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this curated section. Bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving users a range of approaches to explore. Visit the Trending AI Robots page to review the latest featured strategies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
PCVX in upward trend: price rose above 50-day moving average on October 05, 2026
PCVX moved above its 50-day moving average on October 05, 2026 date and that indicates a change from a downward trend to an upward trend. In 35 of 41 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 64 cases where PCVX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on PCVX as a result. In 65 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for PCVX just turned positive on October 05, 2026. Looking at past instances where PCVX's MACD turned positive, the stock continued to rise in 42 of 51 cases over the following month. The odds of a continued upward trend are 82%.
Following a +31.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where PCVX advanced for three days, in 224 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The 10-day moving average for PCVX crossed bearishly below the 50-day moving average on September 25, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PCVX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
PCVX broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PCVX entered a downward trend on October 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 53 (best 1 - 100 worst), indicating steady price growth. PCVX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.144) is normal, around the industry mean (26.780). P/E Ratio (12.594) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 67 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PCVX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in development of vaccines for infectious diseases
Industry Biotechnology
Advertisement